Zaynich

Strategic Shift in Market Entry Mumbai-based pharmaceutical firm Wockhardt has officially decided to self-commercialize its newly approved antibiotic, Zaynich, opting against traditional global licensing deals to retain maximum value. Following recent marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) and significant regulatory progress with the U.S. Food and Drug Administration (USFDA), the company…